Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients

Blood (2024) 144 (Supplement 1): 7236.

https://doi.org/10.1182/blood-2024-197883

Published: 2024

Journal Articles

PKMYT1 Kinase Is an Actionable Synthetically Lethal Target for Del17p Myeloma

Anais Schavgoulidze, Mariateresa Fulciniti, Giulia Giorgetti, Sabrina Maheo, Shuhui Deng, Vanessa Favasuli, Srikanth Talluri, Masood A. Shammas, Luka Pavageau, Anil Aktas-Samur, Mehmet K. Samur, Herve Avet-Loiseau, Jill Corre, Nikhil C. Munshi

Blood (2024) 144 (Supplement 1): 764.

https://doi.org/10.1182/blood-2024-199692

Published: 2024

Journal Articles

Evaluation of D-Vrd Induction/Consolidation Therapy with MRD-Adapted Maintenance in Transplant-Eligible NDMM Patients with Double-Hit Cytogenetic Abnormality (MMY2094)

Chenxing Du, Shuaishuai Zhang, Lugui Qiu, Gang An, Wenqiang Yan, Jian Cui, Weiwei Sui, Shuhui Deng, Yan Xu, Shuhua Yi, Dehui Zou

Blood (2024) 144 (Supplement 1): 7068.

https://doi.org/10.1182/blood-2024-207775

Published: 2024

Journal Articles

Clinical Implications of Residual Immunophenotypically Normal Plasma Cells within Bone Marrow at Various Disease Stages in Multiple Myeloma

Wenqiang Yan, Lihui Shi, Jingyu Xu, Lingna Li, Jian Cui, Chenxing DU, Tengteng Yu, Shuaishuai Zhang, Rui Lv, Weiwei Sui, Shuhui Deng, Yan Xu, Dehui Zou, Lu-Gui Qiu, Mu Hao, Gang An

Blood (2024) 144 (Supplement 1): 1932.

https://doi.org/10.1182/blood-2024-199452

Published: 2024

Journal Articles

BCMA CAR-T Therapy As First-Line Consolidation Treatment in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: An Open Label, Single-Arm, Phase 2 Study (CAREMM-001)

Wenqiang Yan, Chenxing DU, Rui Lv, Tengteng Yu, Shuaishuai Zhang, Tingyu Wang, Weiwei Sui, Shuhui Deng, Yan Xu, Shuhua Yi, Dehui Zou, Lu-Gui Qiu, Gang An

Blood (2024) 144 (Supplement 1): 3385.

https://doi.org/10.1182/blood-2024-199913

Published: 2024

Journal Articles

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients Who Failed or Had Suboptimal Response to Standard First Line Triplet Based Therapy

Blood (2023) 142 (Supplement 1): 6864.

https://doi.org/10.1182/blood-2023-184868

Published: 2023

Journal Articles

Static and Dynamic Assessment to Identify Ultra-High Risk Multiple Myeloma：Analysis for Patients with Overall Survival No More Than Three Years

Yan Xu, Gang An, Shuhui Deng, Weiwei Sui, Wei Liu, Wenyang Huang, Tingyu Wang, Shuhua Yi, Dehui Zou, Lugui Qiu

Blood (2023) 142 (Supplement 1): 6701.

https://doi.org/10.1182/blood-2023-189353

Published: 2023

Journal Articles

Venetoclax Resistance Results in Broad Resistance to Majority of Anti-MM Agents Due to the Suppression of Apoptosis but Can be Overcome By BCMA-Targeted Immunotherapy

Mariateresa Fulciniti, Shuhui Deng, Sanika Dereibal, Vera Joy Weiler, Madhumouli Chatterjee, Jessica Ng Fong, Chandraditya Chakraborty, Rao Prabhala, Masood A. Shammas, Anil Aktas-Samur, Mehmet K. Samur, Annamaria Gulla, Kenneth C. Anderson, Nikhil C Munshi

Blood (2023) 142 (Supplement 1): 3311.

https://doi.org/10.1182/blood-2023-187374

Published: 2023

Journal Articles

The Specific Transcriptional Signature and Clonal Selection of MGUS-like Profile Predict an Exceptionally Favorable Prognosis in Patients with Newly-Diagnosed Multiple Myeloma

Wenqiang Yan, Chen Qiu, Chenxing Du, Shuhui Deng, Weiwei Sui, Yan Xu, Dehui Zou, Weiping Yuan, Lugui Qiu, Gang An

Blood (2023) 142 (Supplement 1): 879.

https://doi.org/10.1182/blood-2023-180351

Published: 2023

Journal Articles

Development and Validation of an Individualized and Weighted Prognostic Model in Patients with Newly Diagnosed Multiple Myeloma

Wenqiang Yan, Xuehan Mao, David E. Mery, Yan Xu, Weiwei Sui, Shuhui Deng, Dehui Zou, John D Shaughnessy, Jr, Kenneth C. Anderson, Fenghuang Zhan, Lugui Qiu, Gang An

Blood (2023) 142 (Supplement 1): 1967.

https://doi.org/10.1182/blood-2023-182598

Published: 2023

Journal Articles

Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in MRD Clones in Multiple Myeloma through Single-Cell Sequencing

Jian Cui, Xiaoyun Li, Shuhui Deng, Lugui Qiu, Xin Gao, Gang An

Blood (2023) 142 (Supplement 1): 4667.

https://doi.org/10.1182/blood-2023-179735

Published: 2023

Journal Articles

Is the Second Revision of the International Staging System (R2-ISS) for Multiple Myeloma Valid in a Real-World Population from China?

Wenqiang Yan, Lingna Li, Huishou Fan, Jingyu Xu, Shuhui Deng, Weiwei Sui, Yan Xu, Dehui Zou, Lugui Qiu, Gang An

Blood (2022) 140 (Supplement 1): 7255–7256.

https://doi.org/10.1182/blood-2022-158751

Published: 2022

Journal Articles

Impact of Neoplastic Plasma Cells in the Stem Cell Collection on Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation

Jingyu Xu, Lingna Li, Wenqiang Yan, Huishou Fan, Jiahui Liu, Chenxing Du, Shuhui Deng, Weiwei Sui, Yan Xu, Lugui Qiu, Gang An

Blood (2022) 140 (Supplement 1): 10011–10012.

https://doi.org/10.1182/blood-2022-165889

Published: 2022

Journal Articles

A Retrospective, Matched Paired Analysis Comparing GBM/GBC Versus BEAM/Beac Conditioning Regimen for Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma

Huimin Liu, Hesong Zou, Wei Liu, Wenyang Huang, Shuhui Deng, Rui Lv, Weiwei Sui, Yan Xu, Shuhua Yi, Tingyu Wang, Mingwei Fu, Gang An, Yaozhong Zhao, Lugui Qiu, Dehui Zou

Blood (2022) 140 (Supplement 1): 10585–10586.

https://doi.org/10.1182/blood-2022-163258

Published: 2022

Journal Articles

The Impact of Dynamic Assessment of Risk Stratification at the Time of Disease Progression in Patients with Multiple Myeloma

Huishou Fan, Wenqiang Yan, Jingyu Xu, Chenxing Du, Weiwei Sui, Shuhui Deng, Dehui Zou, Lugui Qiu, Gang An

Blood (2022) 140 (Supplement 1): 4371–4373.

https://doi.org/10.1182/blood-2022-157223

Published: 2022

Journal Articles

Real-World Retrospective Study of 46 Patients with Macrofocal Multiple Myeloma (MFMM)

Wenqiang Yan, Huishou Fan, Jingyu Xu, Jiahui Liu, Chenxing Du, Shuhui Deng, Weiwei Sui, Yan Xu, Lugui Qiu, Gang An

Blood (2021) 138 (Supplement 1): 3765.

https://doi.org/10.1182/blood-2021-149464

Published: 2021

Journal Articles

Clonal Heterogeneity and Evolutionary Phylogeny of Critical Cytogenetic Aberrations in Multiple Myeloma

Yuting Yan, Xiaoqi Qin, Jiahui Liu, Huishou Fan, Lanting Liu, Zhen Yu, Shuhui Deng, Wei Liu, Dehui Zou, Lugui Qiu, Gang An

Blood (2021) 138 (Supplement 1): 1608.

https://doi.org/10.1182/blood-2021-152794

Published: 2021

Journal Articles

Prognostic Impact of Hyperdiploidy on Multiple Myeloma in the Era of New Agents

Yi Wang, Jing Zhuang, Gang An, MD PhD, Xue-Han Mao, MD, Chenxing Du, MD, Jiahui Liu, Huishou Fan, Shuhui Deng, MD, Yan Xu, MD, Weiwei Sui, Lugui Qiu, MD

Blood (2020) 136 (Supplement 1): 20.

https://doi.org/10.1182/blood-2020-141188

Published: 2020

Journal Articles

The Prognostic Impact of Dynamic Changes of Genetic Risk Stratification in Multiple Myeloma

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-139345

Published: 2020

Journal Articles

Clonal Phylogeny and Evolution of Critical Cytogenetic Aberrations in Multiple Myeloma at Single Cell Level

Yuting Yan, Xiaoqi Qin, Lanting Liu, Shuhui Deng, MD, Jiahui Liu, Huishou Fan, Weiwei Sui, MD, Fu Mingwei, MD, Xue-Han Mao, MD, Zhen Yu, MD, Dehui Zou, MD, Lugui Qiu, MD, Gang An, MD PhD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-143447

Published: 2020

NARROW

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients

PKMYT1 Kinase Is an Actionable Synthetically Lethal Target for Del17p Myeloma

Evaluation of D-Vrd Induction/Consolidation Therapy with MRD-Adapted Maintenance in Transplant-Eligible NDMM Patients with Double-Hit Cytogenetic Abnormality (MMY2094)

Clinical Implications of Residual Immunophenotypically Normal Plasma Cells within Bone Marrow at Various Disease Stages in Multiple Myeloma

BCMA CAR-T Therapy As First-Line Consolidation Treatment in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: An Open Label, Single-Arm, Phase 2 Study (CAREMM-001)

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients Who Failed or Had Suboptimal Response to Standard First Line Triplet Based Therapy

Static and Dynamic Assessment to Identify Ultra-High Risk Multiple Myeloma：Analysis for Patients with Overall Survival No More Than Three Years

Venetoclax Resistance Results in Broad Resistance to Majority of Anti-MM Agents Due to the Suppression of Apoptosis but Can be Overcome By BCMA-Targeted Immunotherapy

The Specific Transcriptional Signature and Clonal Selection of MGUS-like Profile Predict an Exceptionally Favorable Prognosis in Patients with Newly-Diagnosed Multiple Myeloma

Development and Validation of an Individualized and Weighted Prognostic Model in Patients with Newly Diagnosed Multiple Myeloma

Identification of Therapy-Induced Clonal Evolution and Resistance Pathways in MRD Clones in Multiple Myeloma through Single-Cell Sequencing

Is the Second Revision of the International Staging System (R2-ISS) for Multiple Myeloma Valid in a Real-World Population from China?

Impact of Neoplastic Plasma Cells in the Stem Cell Collection on Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation

A Retrospective, Matched Paired Analysis Comparing GBM/GBC Versus BEAM/Beac Conditioning Regimen for Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma

The Impact of Dynamic Assessment of Risk Stratification at the Time of Disease Progression in Patients with Multiple Myeloma

Real-World Retrospective Study of 46 Patients with Macrofocal Multiple Myeloma (MFMM)

Clonal Heterogeneity and Evolutionary Phylogeny of Critical Cytogenetic Aberrations in Multiple Myeloma

Prognostic Impact of Hyperdiploidy on Multiple Myeloma in the Era of New Agents

The Prognostic Impact of Dynamic Changes of Genetic Risk Stratification in Multiple Myeloma

Clonal Phylogeny and Evolution of Critical Cytogenetic Aberrations in Multiple Myeloma at Single Cell Level

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only